合寶豐年(08406.HK)斥945萬人幣購置SMS機器 以生產外科口罩核心材料
合寶豐年(08406.HK)公布,旗下間接全資附屬公司中山市潤和高分子材料製造有限公司(買方),與江蘇三羊紡織機械有限公司(賣方)訂立購買協議,向對方以總合約價945萬元人民幣購置SMS機器。董事認為,受全球整體公共衛生意識增強所推動,紡粘溶噴複合無紡布(生產外科口罩的核心材料)的需求日漸增加。憑藉集團於生產布料方面的專業知識及經驗,認為有能力且擁有足夠資源具經濟效益地擴展其產品組合至其他布料。集團擬設立一條紡粘溶噴複合無紡布生產線以爭取有關業務機會。收購事項為建設生產線製造紡粘溶噴複合無紡布的資本投資。於全面投產後,新生產線的紡粘溶噴複合無紡布總年產能預計約4,088噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.